2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.06 Chen

PP01.06 Chen - Poster

Pdf Summary

The study conducted at Johns Hopkins University focused on the clinicopathologic characteristics and outcomes of patients with KRASG12C mutated NSCLC who had brain metastases. The research involved a retrospective analysis of 186 patients, with 39 of them having brain metastases. The study analyzed various genomic and clinicopathologic characteristics, including common co-mutations like TP53, STK11, and KEAP1.<br /><br />The findings revealed that patients with brain metastases had a higher frequency of these co-mutations compared to those without brain involvement. The study also highlighted treatment patterns for brain metastases, with radiation therapy being the most common intervention, followed by surgical resection. Overall survival outcomes were similar between patients with brain metastases at diagnosis and those developing metastases during treatment.<br /><br />The researchers emphasized the importance of including patients with brain metastases in clinical trials for KRASG12C targeted therapies. Understanding the clinicopathologic features affecting treatment response can help identify those who may benefit most from these therapies. The study underscores the need for larger studies to assess the efficacy of current treatment modalities and the impact of co-mutations on outcomes in KRASG12C mutated NSCLC with brain metastases.

Keywords

Johns Hopkins University

KRASG12C mutated NSCLC

brain metastases

clinicopathologic characteristics

co-mutations

treatment patterns

overall survival outcomes

clinical trials

targeted therapies

larger studies